Zai Lab’s Zocilurtatug Pelitecan (Zoci, Formerly ZL-1310) Demonstrates High Response Rates, Encouraging Durability and Well-Tolerated Safety Profile in First-Line Extensive-Stage Small Cell Lung Cancer
Key Highlights
- ➤Zoci plus atezolizumab delivered 81.8% confirmed response rate in first-line ES-SCLC
- ➤Six-month progression-free survival reached 81.9% for the 1.6 mg/kg doublet
- ➤Median progression-free survival and response duration were not reached after 10-month follow-up
- ➤Grade ≥3 zoci-related adverse events affected 9.1% of doublet patients
- ➤Global randomized Phase 3 study expected to initiate by year-end 2026
Expert Statements
Rafael G. Amado, President, Head of Global Research and Development at Zai Lab
“Despite advances in treatment, extensive-stage small-cell lung cancer remains a devastating disease, with many patients experiencing disease progression within approximately five months of initiating standard first-line treatment”
Rafael G. Amado, President, Head of Global Research and Development at Zai Lab
“The high confirmed response rate, encouraging durability, and well-tolerated safety profile we are seeing with a standard chemotherapy-free regimen are particularly compelling.”
Rafael G. Amado, President, Head of Global Research and Development at Zai Lab
“We believe zoci’s combination of efficacy and safety positions it to become an ADC backbone of choice in small-cell lung cancer, including in combination with immunotherapies.”
Rafael G. Amado, President, Head of Global Research and Development at Zai Lab
“We are preparing to initiate a global Phase 3 trial of zoci and an Immuno-Oncology (IO) regimen and continue to evaluate the potential of combinations with T-cell engagers and IO.”
Pedro Rocha, Study investigator and medical oncologist at Vall d’Hébron University Hospital in Barcelona, Spain
“The zoci and atezolizumab doublet demonstrated substantial early antitumor activity with high, durable responses and a favorable safety profile, which are very encouraging results for patients with extensive-stage small cell lung cancer.”
Pedro Rocha, Study investigator and medical oncologist at Vall d’Hébron University Hospital in Barcelona, Spain
“Importantly, this platinum-free regimen may allow patients to stay on treatment longer with potentially fewer side effects.”
Pedro Rocha, Study investigator and medical oncologist at Vall d’Hébron University Hospital in Barcelona, Spain
“These results support further exploration of zoci in combination regimens.”
Pedro Rocha, Study investigator and medical oncologist at Vall d’Hébron University Hospital in Barcelona, Spain
“I look forward to seeing how this profile evolves as the clinical program advances.”
Zai Lab’s Zocilurtatug Pelitecan (Zoci, Formerly ZL-1310) Demonstrates High Response Rates, Encouraging Durability and Well-Tolerated Safety Profile in First-Line Extensive-Stage Small Cell Lung Cancer
* At the recommended Phase 3 dose (RP3D) of 1.6 mg/kg, zoci plus atezolizumab achieved a confirmed objective response rate of 81.8% (27/33) and an estimated 6-month progression-free survival rate of 81.9% (n=33) in 1L ES-SCLC
Get started
Create a free account to read the full story.